{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Llorente X"],"funding":["Spanish Ministry of Science and Innovation"],"pagination":["8053"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10179084"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["24(9)"],"pubmed_abstract":["Nanocarriers, and especially nanostructured lipid carriers (NLC), represent one of the most effective systems for topical drug administration. NLCs are biodegradable, biocompatible and provide a prolonged drug release. The glutamate release inhibitor Riluzole (RLZ) is a drug currently used for amyotrophic lateral sclerosis (ALS), with anti-proliferative effects potentially beneficial for diseases with excessive cell turnover. However, RLZ possesses low water solubility and high light-sensibility. We present here optimized NLCs loaded with RLZ (RLZ-NLCs) as a potential topical treatment. RLZ-NLCs were prepared by the hot-pressure homogenization method using active essential oils as liquid lipids, and optimized using the design of experiments approach. RLZ-NLCs were developed obtaining optim"],"journal":["International journal of molecular sciences"],"pubmed_title":["Riluzole-Loaded Nanostructured Lipid Carriers for Hyperproliferative Skin Diseases."],"pmcid":["PMC10179084"],"funding_grant_id":["PID2021-122187NB-C32","PID2021-126249OA-I00","PID2020-114477RB-I00"],"pubmed_authors":["Bonilla L","Agudelo MG","Llorente X","Manils J","Sanchez-Lopez E","Garcia ML","Pujol M","Lopez-Ramajo D","Soler C","Espina M","Gong RC","Filgaira I","Esteruelas G"],"additional_accession":[]},"is_claimable":false,"name":"Riluzole-Loaded Nanostructured Lipid Carriers for Hyperproliferative Skin Diseases.","description":"Nanocarriers, and especially nanostructured lipid carriers (NLC), represent one of the most effective systems for topical drug administration. NLCs are biodegradable, biocompatible and provide a prolonged drug release. The glutamate release inhibitor Riluzole (RLZ) is a drug currently used for amyotrophic lateral sclerosis (ALS), with anti-proliferative effects potentially beneficial for diseases with excessive cell turnover. However, RLZ possesses low water solubility and high light-sensibility. We present here optimized NLCs loaded with RLZ (RLZ-NLCs) as a potential topical treatment. RLZ-NLCs were prepared by the hot-pressure homogenization method using active essential oils as liquid lipids, and optimized using the design of experiments approach. RLZ-NLCs were developed obtaining optim","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Apr","modification":"2025-04-18T13:56:57.821Z","creation":"2025-04-06T23:49:27.842Z"},"accession":"S-EPMC10179084","cross_references":{"pubmed":["37175765"],"doi":["10.3390/ijms24098053"]}}